Physiomics plc announced that it has been awarded a further contract by existing client, Numab Therapeutics ("Numab"). The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in support of one of Numab's oncology assets entering the clinic and will help inform dose and scheduling decisions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.55 GBX | +3.33% | 0.00% | -3.12% |
Mar. 18 | Transcript : Physiomics Plc, H1 2024 Earnings Call, Mar 18, 2024 | |
Mar. 18 | Physiomics celebrates "substantial" contract with old client | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.12% | 2.55M | |
-5.75% | 130B | |
+8.08% | 69.31B | |
-17.07% | 37.79B | |
+9.36% | 36.04B | |
-9.72% | 27.88B | |
-12.29% | 16.12B | |
+8.02% | 14.74B | |
+11.64% | 10.56B | |
-26.13% | 4.74B |
- Stock Market
- Equities
- PYC Stock
- News Physiomics Plc
- Physiomics plc Announces Contract Award